---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-017544"
form_type: "8-K/A"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:28:42.603548+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Onconetix completes Proteomedix acquisition; target shows $27.2M deficit, going concern

## Summary
- Proteomedix 2022 revenue $392K, net loss $2.04M; accumulated deficit $27.2M as of Dec 31, 2022.
- Total liabilities $6.86M vs stockholders' deficit $5.79M; cash only $470K at year-end 2022.
- Auditor's report includes substantial doubt about Proteomedix's ability to continue as going concern.
- Onconetix issued stock for 100% of Proteomedix equity on Dec 15, 2023; acquisition previously disclosed.
- Pro forma financials and unaudited interim statements through Sep 30, 2023 now filed with SEC.

## SEC filing metadata
- accession: 0001213900-24-017544
- form_type: 8-K/A
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 9.01, 8.01, 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/ea0200807-8ka2_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-017544
- JSON: https://secwatch.observer/filing/0001213900-24-017544.json
- Plain text: https://secwatch.observer/filing/0001213900-24-017544.txt

## Key facts
- M&A Transactions
  Onconetix, Inc. completed an acquisition involving Proteomedix AG for share exchange (closed 2023-12-15).
  - Action: acquisition
  - Counterparty: Proteomedix AG
  - Consideration: share exchange
  - Closing: 2023-12-15
  source text: the Company consummated a share exchange transaction (the “ Share Exchange ”) with Proteomedix on December 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.